Bli medlem
Bli medlem

Du är här

2016-10-17

MorphoSys AG: MorphoSys Presents Updated Clinical Results for MOR202 at Medical Conference

MorphoSys AG / MorphoSys Presents Updated Clinical Results for MOR202 at
Medical Conference. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
In Ongoing Phase 1/2a Study, Anti-CD38 Antibody Continues to Show Encouraging
Clinical Response Rates in Heavily Pre-Treated Multiple Myeloma Patients

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) presented
updated safety and efficacy data from an ongoing phase 1/2a clinical study
evaluating MOR202, an investigational antibody targeting CD38, alone and in
combination with immunomodulatory drugs (IMiDs) lenalidomide (Len) and
pomalidomide (Pom), plus dexamethasone (Dex) in heavily pre-treated patients
with relapsed/refractory multiple myeloma (MM). Data were presented during a
poster presentation at the 2016 annual meeting of the German, Austrian and
Swiss Societies for Hematology and Medical Oncology in Leipzig/Germany.

Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG, commented:
"We are very pleased that these results are consistent with earlier data from
the ongoing trial and show further improved responses with more patients
being evaluable for efficacy and safety assessment. In addition to the very
short infusion-time, we are particularly interested in the efficacy results
in patients treated with MOR202 plus pomalidomide, who had a median of four
prior therapies. The dose escalation study is ongoing as planned, currently
focusing on the highest dose cohorts of 16 mg/kg MOR202 in combination with
pomalidomide and lenalidomide."

78 % of evaluable patients (7 out of 9) treated with MOR202 in combination
with Len/Dex showed an objective response (i.e. complete response (CR) or
partial response (PR)). In the patient group treated with MOR202 plus Pom, 60
% (3 out of 5) showed an objective response, with two patients achieving a
complete remission (CR). Considering only patients enrolled per protocol, the
ORR (objective response rate) in this patient group rises to 75 % and the CR
rate to 50 %. Of the patients treated with MOR202 alone, so far 29 % (5 out
of 17) showed an objective response. Median time to response was six weeks
with most responses deepening over time. 12 of the 15 responses are currently
ongoing for up to 56 weeks.

When MOR202 was given as a 2-hour infusion up to the highest dose of 16 mg/kg,
92 % of patients treated showed no infusion-related reactions (IRRs). IRRs
occurred in just 8 % of patients (3 % of grade 1, 5 % of grade 2) and were
mainly limited to the first infusion. No unexpected safety signals were
observed. The most frequent adverse events of grade 3 or higher were, as
expected, hematological and included lymphopenia, neutropenia and leukopenia.
No treatment-related deaths were reported.

Biomarker data on bone marrow plasma cells suggests that during MOR202
therapy, expression of CD38 as the target molecule for MOR202 seems to be
preserved.

The poster presented at the DGHO Annual Meeting can be downloaded from the
Company'swebsite.

About MOR202 and the ongoing phase 1/2a study in multiple myeloma
The investigational drug MOR202 is a fully human HuCAL antibody targeting
CD38, a highly expressed and validated target in multiple myeloma. Data are
from an ongoing clinical phase 1/2a, open-label, multi-center,
dose-escalation study conducted in several sites in Germany and Austria. The
study is evaluating the safety and preliminary efficacy of MOR202 alone and
in combination with the immunomodulatory drugs pomalidomide (Pom) and
lenalidomide (Len) plus dexamethasone (Dex) in patients with
relapsed/refractory multiple myeloma. The primary endpoints of the trial are
the safety, tolerability and recommended dose of MOR202 alone and in
combination with the IMiDs. Secondary outcome measures are pharmacokinetics
and preliminary efficacy based on overall response rate, duration of
response, time-to-progression, and progression-free survival.

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a
therapeuticpipelineof more than 100 human antibody drug candidates for the
treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name
just a few. With its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys,
visithttp://www.morphosys.com.

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®,
100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are
registered trademarks of the MorphoSys Group.

This communication contains certain forward-looking statements concerning the
MorphoSys group of companies, The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and
involve risks and uncertainties, Should actual conditions differ from the
Company's assumptions, actual results and actions may differ from those
anticipated, MorphoSys does not intend to update any of these forward-looking
statements as far as the wording of the relevant press release is concerned.

For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications&IR

Jochen Orlowski
Associate Director Corporate Communications&IR

Alexandra Goller
Senior Manager Corporate Communications&IR

Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com

Media release (PDF)
http://hugin.info/130295/R/2048492/766279.pdf

---------------------------------------

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.